» Articles » PMID: 20360935

Circulating MiR-210 As a Novel Hypoxia Marker in Pancreatic Cancer

Overview
Journal Transl Oncol
Specialty Oncology
Date 2010 Apr 3
PMID 20360935
Citations 156
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNA are small noncoding transcripts involved in many cellular mechanisms, including tumorigenesis. miR-210, in particular, is induced by hypoxia and correlates with adverse outcomes in certain cancers. Because pancreatic adenocarcinomas exhibit extremely hypoxic signatures, we hypothesized that miR-210 may serve as a diagnostic marker for screening or surveillance for pancreatic cancer. Plasma samples were obtained from newly diagnosed pancreatic cancer patients and age-matched noncancer controls. miRNA was extracted directly from plasma and reverse-transcribed to complementary DNA. A known quantity of synthetic Caenorhabditis elegans miR-54 (celmiR-54) was added for normalization. miR-210 and cel-miR-54 were then measured using quantitative reverse transcription polymerase chain reaction. An initial cohort of 11 pancreatic cancer patients and 14 age-matched controls was used as the test set and a second cohort of 11 pancreatic cancer patients and 11 controls was used as the validating set in this study. miR-210 was reliably detected and quantified, with a statistically significant four-fold increase in expression in pancreatic cancer patients compared with normal controls (P < .00004) in the test set. This difference was confirmed in the validation group (P < .018). In summary, circulating miR-210 levels are elevated in pancreatic cancer patients and may potentially serve as a useful biomarker for pancreatic cancer diagnosis.

Citing Articles

MicroRNAs in pancreatic cancer drug resistance: mechanisms and therapeutic potential.

Dong F, Zhou J, Wu Y, Gao Z, Li W, Song Z Front Cell Dev Biol. 2025; 12:1499111.

PMID: 39882259 PMC: 11774998. DOI: 10.3389/fcell.2024.1499111.


The Past, Present, and Future of Biomarkers for the Early Diagnosis of Pancreatic Cancer.

Vitale F, Zileri Dal Verme L, Paratore M, Negri M, Nista E, Ainora M Biomedicines. 2025; 12(12.

PMID: 39767746 PMC: 11673965. DOI: 10.3390/biomedicines12122840.


Using microRNAs Networks to Understand Pancreatic Cancer-A Literature Review.

Przybyszewski O, Mik M, Nowicki M, Kusinski M, Mikolajczyk-Solinska M, Sliwinska A Biomedicines. 2024; 12(8).

PMID: 39200178 PMC: 11351910. DOI: 10.3390/biomedicines12081713.


Urinary microRNA-210-3p as a novel and non-invasive biomarker for the detection of pancreatic cancer, including intraductal papillary mucinous carcinoma.

Imamura T, Komatsu S, Nishibeppu K, Kiuchi J, Ohashi T, Konishi H BMC Cancer. 2024; 24(1):907.

PMID: 39069624 PMC: 11283702. DOI: 10.1186/s12885-024-12676-x.


Role of MicroRNA in Hypoxic Tumours and their Potential as Biomarkers for Early Detection of Cancer.

Jayashree P, Kalpita M, Judith T, Singh A, Ashwin K Curr Mol Med. 2024; 24(5):525-536.

PMID: 38310548 DOI: 10.2174/0115665240268661231128094831.


References
1.
Camps C, Buffa F, Colella S, Moore J, Sotiriou C, Sheldon H . hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008; 14(5):1340-8. DOI: 10.1158/1078-0432.CCR-07-1755. View

2.
Koong A, Mehta V, Le Q, Fisher G, Terris D, Brown J . Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys. 2000; 48(4):919-22. DOI: 10.1016/s0360-3016(00)00803-8. View

3.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

4.
Ivan M, Harris A, Martelli F, Kulshreshtha R . Hypoxia response and microRNAs: no longer two separate worlds. J Cell Mol Med. 2008; 12(5A):1426-31. PMC: 3918058. DOI: 10.1111/j.1582-4934.2008.00398.x. View

5.
Wang J, Chen J, Chang P, Leblanc A, Li D, Abbruzzesse J . MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila). 2009; 2(9):807-13. PMC: 5859193. DOI: 10.1158/1940-6207.CAPR-09-0094. View